| First Author | Zhang S | Year | 2019 |
| Journal | Mol Immunol | Volume | 114 |
| Pages | 260-268 | PubMed ID | 31398665 |
| Mgi Jnum | J:292675 | Mgi Id | MGI:6435621 |
| Doi | 10.1016/j.molimm.2019.07.029 | Citation | Zhang S, et al. (2019) SKI and SMAD4 are essential for IL-21-induced Th17 differentiation. Mol Immunol 114:260-268 |
| abstractText | Th17 cells are essential for the pathogenesis of inflammatory and autoimmune diseases. In the presence of TGF-beta, the differentiation of Th17 cells can be induced by inflammatory cytokines, especially IL-6, which is mainly produced by antigen presenting cells (APCs); or IL-21, which is derived from T cells. IL-21 is required for IL-6-induced Th17 cell differentiation. However, the key regulators and underlying mechanisms for IL-21-induced Th17 differentiation is still elusive. Here we show that SMAD4 is a key regulator in IL-21-induced Th17 differentiation. SMAD4 deficient naive T cells can differentiate into Th17 cells in the absence of TGF-beta signaling, and these Th17 cells are pathogenic during EAE. SMAD4 represses Rorc mRNA transcription to constrain IL-21-induced Th17 differentiation in the absence of TGF-beta signaling. While in the presence of TGF-beta, SMAD4 losses its suppressive ability due to the degradation of SKI. Mutation of Y429A or A432E on SMAD4 disrupts the interaction of SKI from SMAD4 and eliminates SMAD4 mediated suppression of Th17 differentiation. SMAD4 is indispensable for SKI binding to Rorc promoter region to regulate Th17 differentiation. Moreover, activin can induce Th17 differentiation in combination with IL-21, and the process is also subjected to the control of SKI and SMAD4. This study therefore elucidates critical mechanism for IL-21-induced Th17 differentiation to indicate SKI and SMAD4 as potential therapeutic targets for treating autoimmune diseases. |
